Should I buy AbbVie (ABBV) stock or is it too late?
⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (830 calls tested). It aims for $310 (+13 %), call made on October 8, 2026, maturing on October 8, 2027 (6 d ago).
Firm-by-firm track record on AbbVie
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| RBC Capital | 100 % | +27.8 % | 6 | $280 +2% |
| UBS | 100 % | +24.3 % | 9 | $275 +0% |
| JP Morgan | 83 % | +19.6 % | 6 | $300 +9% |
| Piper Sandler | 93 % | +17.1 % | 15 | $303 +10% |
| Citigroup | 100 % | +16.7 % | 14 | $260 -5% |
| Evercore ISI Group | 83 % | +16.4 % | 6 | $260 -5% |
| Cantor Fitzgerald | 100 % | +13.6 % | 9 | $290 +6% |
| BMO Capital | 88 % | +13.6 % | 24 | $300 +9% |
✅ Reasons to believe
- 86% of analysts rate it a buy (Buy consensus, 22 ratings) — a sign of market conviction.
- The most reliable firm on ABBV, RBC Capital (100% hit rate, 6 scored calls), targets $280 (call made on October 13, 2026, maturing on October 13, 2027) (+2%) in its most recent call, and $260 (call made on February 25, 2026, maturing on February 25, 2027) (-5%) in the one coming due soonest.
- 7 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
- Pays a dividend (2.7% yield), raised for 12 years — regular income on top of potential upside.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 22 ratings, 3 are neutral.
- Limited upside: the median target is only +6% from the current price.
- High valuation (P/E ~78): strong growth is already "priced in", leaving little room for error.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on ABBV
Median target $290 (+6%) · 22 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in AbbVie now?
We won't decide for you. The facts: 86% of analysts rate it a buy, median target $290 (+6%), and RBC Capital (most reliable on ABBV, 100%) targets $280. Weigh that against valuation (P/E ~78). This is not personalized advice.
Is it too late to invest in AbbVie?
Not according to analysts: the median target ($290) is still +6% above the current price ($274) (most reliable on ABBV: RBC Capital, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is AbbVie still worth investing in?
It depends on the gap between the price ($274) and its estimated value: analysts target $290 on median (+6%), with 86% buys (most reliable on ABBV: RBC Capital, 100%). Cross-check with their real reliability on ABBV and the cautions above. Information, not advice.
What's the main risk in buying ABBV?
The consensus is not unanimous: of 22 ratings, 3 are neutral.
→ Go deeper: the full AbbVie profile (consensus, analyst reliability, price target, performance).